<DOC>
	<DOCNO>NCT02986737</DOCNO>
	<brief_summary>Trial ACURATE neo ( TM ) Aortic Bioprosthesis Implantation use ACURATE TA ( TM ) LP Transapical Delivery System Patients Severe Aortic Stenosis evaluate Safety performance study device</brief_summary>
	<brief_title>ACURATE Neo™ Aortic Bioprosthesis Implantation Using ACURATE TA™ LP Transapical Delivery System Patients With Severe Aortic Stenosis</brief_title>
	<detailed_description>This single arm , prospective , multicenter non randomise open trial treatment patient severe aortic stenosis conventional aortic valve replacement ( AVR ) via open heart surgery consider high risk . All patient follow 5 year intervention . The primary objective evaluate safety performance study device patient present severe aortic stenosis consider high risk surgery Secondary objective evaluate adverse event study device performance .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>1 . Patient 75 year age old 2 . Severe aortic stenosis define : Mean aortic gradient &gt; 40mmHg Peak jet velocity &gt; 4.0m/sor Aortic valve area &lt; 1.0cm2 3 . High risk candidate conventional AVR define : STS score ≥ 10 ￼￼￼￼Multidisciplinary heart team ( cardiologist cardiac surgeon ) consensus patient surgical candidate conventional AVR due significant co morbid condition unrelated aortic stenosis 4 . NYHA Functional Class &gt; II 5 . Multidisciplinary heart team ( cardiologist cardiac surgeon ) consensus transapical approach suitable TAVI access route 6 . Aortic annulus diameter ≥ 21mm ≤ 27mm CT TEE 7 . Patient willing participate study provide sign informed consent 1 . Congenital unicuspid bicuspid aortic valve 2 . Extreme eccentricity calcification 3 . Severe mitral regurgitation ( &gt; Grade 2 ) 4 . Preexisting prosthetic heart valve position / prosthetic ring 5 . LV apex accessible via transapical access due severe chest deformity 6 . Previous surgery LV use patch , Dor procedure 7 . Presence apical LV thrombus 8 . Calcified pericardium 9 . Septal hypertrophy unacceptable transapical procedure 10 . Transesophageal echocardiogram ( TEE ) contraindicate 11 . ECHO evidence intracardiac mass , thrombus , vegetation 12 . LVEF &lt; 30 % ECHO 13 . Emergency procedure preimplant include CAD require revascularization 14 . Any percutaneous intervention , except balloon valvuloplasty ( BAV ) within 1 month prior implant procedure 15 . Acute myocardial infarction within 1 month prior implant procedure 16 . Previous TIA stroke within 3 month prior implant procedure 17 . Active gastrointestinal ( GI ) bleed within 3 month prior implant procedure 18 . Scheduled surgical percutaneous procedure perform prior 30 day visit 19 . History bleed diathesis coagulopathy refusal blood transfusion 20 . Systolic pressure &lt; 80mmHg , cardiogenic shock , need inotropic support IABP 21 . Primary hypertrophic obstructive cardiomyopathy ( HOCM ) 22 . Active infection , endocarditis pyrexia 23 . Hepatic failure ( &gt; Child B ) 24 . Chronic renal dysfunction serum creatinine &gt; 2.5 mg/dL renal dialysis 25 . Refusal surgery 26 . Severe COPD require home oxygen 27 . Neurological disease severely affect ambulation , daily functioning , dementia 28 . Life expectancy &lt; 12 month due noncardiac comorbid condition 29 . Contraindication study medication , contrast medium , allergy nitinol 30 . Currently participate investigational drug another device study</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>TAVI</keyword>
	<keyword>Aortic Stenosis</keyword>
	<keyword>Transcatether Aortic Valve Implantation</keyword>
</DOC>